Brain

Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share

Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous…

3 months ago

Luminopia Partners with Pokémon to Expand Its Curated Content Library for Pediatric Amblyopia Patients

Children using Luminopia now have access to hundreds of episodes from the original Pokémon animated series, making amblyopia treatment even…

3 months ago

Longevity Takes the Spotlight: Global Wellness Summit Announces First Wave of Trailblazing Speakers for 19th Annual Gathering

From gene editing breakthroughs to AI-driven drug discovery to epigenetic interventions, this year's Summit explores the radical advances reshaping how…

3 months ago

The Brain Aneurysm Foundation Announces its 2025 Research Grant Recipients

Close to $600,000 in Funding Provided to 14 Academic Researchers from Across the US to Advance New Innovations to Predict,…

3 months ago

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms

SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…

3 months ago

Cumulus Neuroscience Appoints Robert Ballantine to Board of Directors

BELFAST, Northern Ireland, Sept. 10, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing…

3 months ago

NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the ‘trial and error’ approach to finding the right antidepressant

NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,…

3 months ago

NeuroKaire launches first-of-its-kind clinical test in the US, expected to dramatically reduce the ‘trial and error’ approach to finding the right antidepressant

NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,…

3 months ago

Understood.org Unveils “Through My Eyes” Immersive Platform, Offering Glimpses Into the Daily Lives of Kids With ADHD, Dyslexia, and Dyscalculia

The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking…

3 months ago

Understood.org Unveils “Through My Eyes” Immersive Platform, Offering Glimpses Into the Daily Lives of Kids With ADHD, Dyslexia, and Dyscalculia

The free digital tool uses simulations, videos, and expert resources to start conversations and challenge assumptions about learning and thinking…

3 months ago